The DF/HCC Prostate Cancer SPORE Tissue and Pathology Core has provided and will continue to provide collaborating investigators multiple pathology services including histology, immunohistochemistry, in situ hybridization, fluorescent in situ hybridization (FISH), computer-assisted image analysis, laser capture microdissection, and the generation of and access to tissue microarrays (TMAs). Our overarching goal is to create a seamless informatics link between the extensive existing tissue resources among the Dana- Farber/Harvard Cancer Center (DF/HCC) hospitals and collaborators. Thus, one of the major goals of this Core is to maintain and grow an existing tissue and blood resource (henceforth referred to as """"""""biobank""""""""), linked to clinical outcome data, behind a secure data management system that will be available to DF/HCC SPORE investigators as well as SPORE investigators at other institutions. In this regard there is and will continue to be close collaboration between the Tissue and Pathology Core and the Biostatistical and Computational Biology Core. The guiding principles of this Core are now listed: 1) Successful translational research requires a wide range of well-annotated human analytes, mouse models, xenografts, and cell lines. 2) Patient protection and regulatory issues are the top priority of any biobank. 3) Access to samples and rules of usage (governance) need to- be determined prior to performing experiments. 4) Data generated from each sample increase that sample's value. 5) The biobank should facilitate research of qualified investigators regardless of their affiliation to the DF/HCC Prostate Cancer SPORE (i.e., outstanding research is encouraged from all corners of the world). 6) Pre-analytic variability of samples should be monitored and standard operating procedures (SOPs) should be employed when known. 7) Synergy with pre-existing programs leads to economy of effort. 8) Given limited resources, the biobank should focus first on the five SPORE Projects and the Developmental Projects and Projects of the Career Development Awardees. 9) Bioinformatics enhances the use of data generated from biobank samples.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090381-08
Application #
7890601
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2009-07-01
Project End
2012-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
8
Fiscal Year
2009
Total Cost
$263,236
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Pakula, Hubert; Linn, Douglas E; Schmidt, Daniel R et al. (2018) Protocols for Studies on TMPRSS2/ERG in Prostate Cancer. Methods Mol Biol 1786:131-151
Elfandy, Habiba; Armenia, Joshua; Pederzoli, Filippo et al. (2018) Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res :
Han, W; Gao, S; Barrett, D et al. (2018) Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Oncogene 37:710-721
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Russo, Joshua W; Liu, Xiaming; Ye, Huihui et al. (2018) Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett 438:97-104
Pettersson, Andreas; Gerke, Travis; Penney, Kathryn L et al. (2018) MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:201-207
Tsang, Sabrina H; Peisch, Samuel F; Rowan, Brendan et al. (2018) Association between Trichomonas vaginalis and prostate cancer mortality. Int J Cancer :
Arai, Seiji; Jonas, Oliver; Whitman, Matthew A et al. (2018) Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clin Cancer Res 24:5458-5470
Francini, Edoardo; Gray, Kathryn P; Xie, Wanling et al. (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78:889-895
Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362

Showing the most recent 10 out of 261 publications